<DOC>
	<DOCNO>NCT01992276</DOCNO>
	<brief_summary>The purpose study evaluate rate decline quantitative viral load measure hospitalized patient Influenza A infection</brief_summary>
	<brief_title>Assessment Efficacy CR8020 CR6261 , Monoclonal Antibodies , Against Influenza Infection</brief_title>
	<detailed_description>This randomize , placebo-controlled , double-blind phase IIa proof-of-concept study , design evaluate effect CR8020 , CR6261 , placebo hospitalize patient influenza A infection receive standard care . Up 262 participant randomize receive 30 mg/kg CR8020 , 30 mg/kg CR6261 , placebo . The study duration approximately 117 day participant . Prior enrollment , participant screen assess eligibility . Eligible participant randomize CR8020 , CR6261 , placebo study drug administer Day 1 . Participants follow 115 day 9 visit Days 2 8 , Day 29 , Day 116 ( end study ) . After hospital discharge , remain follow-up visit perform outpatient visit .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participant require hospitalization/ Each participant legally acceptable representative must sign informed consent form/ Participant must able start infusion within 36 hour time screen specimen collected/ A woman must either childbearing potential childbearing potential agrees practice two form highly effective method birth control/ A woman childbearing potential must negative serum ( beta human chorionic gonadotropin [ beta hCG ] ) screening/ A man sexually active woman childbearing potential vasectomy must agree use barrier method birth control/ Participant female pregnant breastfeeding/ Participant undergoing peritoneal dialysis , hemodialysis hemofiltration/ Participant presence preexist illness , opinion investigator , would place participant unreasonably increase risk participation study/ Participant prior treatment experimental mAb ; receipt IgG within 3 month chronic mAb treatment prior enrollment/ Participant know suspected hypersensitivity CR8020 CR6261 excipients ( sucrose , Lhistidine Lhistidine monohydrochloride , polysorbate 20 ) / Participant receive investigational product ( include investigational vaccine ) use investigational medical device within 60 day plan start treatment , currently enrol interventional investigational study , employee investigational site/</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Virus</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Immunization</keyword>
	<keyword>Treatment</keyword>
</DOC>